Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Artigo em Inglês | MEDLINE | ID: mdl-38735831

RESUMO

INTRODUCTION: Lung cancer (LC) screening detects tumors early. The prospective GESIDA 8815 study was designed to assess the usefulness of this strategy in HIV + people (PLHIV) by performing a low-radiation computed tomography (CT) scan. PATIENTS AND METHODS: 371 heavy smokers patients were included (>20 packs/year), >45 years old and with a CD4+ <200 mm3 nadir. One visit and CT scan were performed at baseline and 4 for follow-up time annually. RESULTS: 329 patients underwent the baseline visit and CT (CT0) and 206 completed the study (CT1 = 285; CT2 = 259; CT3 = 232; CT4 = 206). All were receiving ART. A total >8 mm lung nodules were detected, and 9 early-stage PCs were diagnosed (4 on CT1, 2 on CT2, 1 on CT3 and 2 on CT4). There were no differences between those who developed LC and those who did not in sex, age, CD4+ nadir, previous lung disease, family history, or amount of packets/year. At each visit, other pathologies were diagnosed, mainly COPD, calcified coronary artery and residual tuberculosis lesions. At the end of the study, 38 patients quit smoking and 75 reduced their consumption. Two patients died from LC and 16 from other causes (p = 0.025). CONCLUSIONS: The design of the present study did not allow us to define the real usefulness of the strategy. Adherence to the test progressively decreased over time. The diagnosis of other thoracic pathologies is very frequent. Including smokers in an early diagnosis protocol for LC could help to quit smoking.

2.
Int J Mol Sci ; 23(18)2022 Sep 07.
Artigo em Inglês | MEDLINE | ID: mdl-36142255

RESUMO

SARS-CoV-2 is a new coronavirus characterized by a high infection and transmission capacity. A significant number of patients develop inadequate immune responses that produce massive releases of cytokines that compromise their survival. Soluble factors are clinically and pathologically relevant in COVID-19 survival but remain only partially characterized. The objective of this work was to simultaneously study 62 circulating soluble factors, including innate and adaptive cytokines and their soluble receptors, chemokines and growth and wound-healing/repair factors, in severe COVID-19 patients who survived compared to those with fatal outcomes. Serum samples were obtained from 286 COVID-19 patients and 40 healthy controls. The 62 circulating soluble factors were quantified using a Luminex Milliplex assay. Results. The patients who survived had decreased levels of the following 30 soluble factors of the 62 studied compared to those with fatal outcomes, therefore, these decreases were observed for cytokines and receptors predominantly produced by the innate immune system-IL-1α, IL-1α, IL-18, IL-15, IL-12p40, IL-6, IL-27, IL-1Ra, IL-1RI, IL-1RII, TNFα, TGFα, IL-10, sRAGE, sTNF-RI and sTNF-RII-for the chemokines IL-8, IP-10, MCP-1, MCP-3, MIG and fractalkine; for the growth factors M-CSF and the soluble receptor sIL2Ra; for the cytokines involved in the adaptive immune system IFNγ, IL-17 and sIL-4R; and for the wound-repair factor FGF2. On the other hand, the patients who survived had elevated levels of the soluble factors TNFß, sCD40L, MDC, RANTES, G-CSF, GM-CSF, EGF, PDGFAA and PDGFABBB compared to those who died. Conclusions. Increases in the circulating levels of the sCD40L cytokine; MDC and RANTES chemokines; the G-CSF and GM-CSF growth factors, EGF, PDGFAA and PDGFABBB; and tissue-repair factors are strongly associated with survival. By contrast, large increases in IL-15, IL-6, IL-18, IL-27 and IL-10; the sIL-1RI, sIL1RII and sTNF-RII receptors; the MCP3, IL-8, MIG and IP-10 chemokines; the M-CSF and sIL-2Ra growth factors; and the wound-healing factor FGF2 favor fatal outcomes of the disease.


Assuntos
COVID-19 , Interleucina-27 , Quimiocina CCL5 , Quimiocina CX3CL1 , Quimiocina CXCL10 , Citocinas , Fator de Crescimento Epidérmico , Fator 2 de Crescimento de Fibroblastos , Fator Estimulador de Colônias de Granulócitos , Fator Estimulador de Colônias de Granulócitos e Macrófagos , Humanos , Proteína Antagonista do Receptor de Interleucina 1 , Interleucina-10 , Subunidade p40 da Interleucina-12 , Interleucina-15 , Interleucina-17 , Interleucina-18 , Interleucina-6 , Interleucina-8 , Fator Estimulador de Colônias de Macrófagos , SARS-CoV-2 , Fator de Crescimento Transformador alfa , Fator de Necrose Tumoral alfa
3.
Artigo em Inglês | MEDLINE | ID: mdl-26305901

RESUMO

The addition of wood chips as a co-substrate can promote the degradation of oil in soil. Therefore, in the present study, the tree species-specific impact of wood chips of Scots pine (Pinus sylvestris L.), Norway spruce (Picea abies L.) and Western balsam poplar (Populus trichocarpa L.) on the degradation of crude oil was tested in beach sand in a 4-week incubation experiment. The CO2-C release increased in the order of control without wood chips < +spruce < +pine < +poplar. Initial and final hydrocarbon concentrations (C10 to C40), as indicators for the oil degradation, were determined with gas chromatography-flame ionization detection (GC-FID). The degradation increased for the light fraction (C10 to C22), the heavy fraction (C23 to C40) as well as the whole range (C10 to C40) in the order of control without wood chips (f(degrad.) = 23% vs. 0% vs. 12%) < +poplar (f(degrad.) = 49% vs. 19% vs. 36%) < +spruce (f(degrad.) = 55% vs. 34% vs. 46%) < +pine (f(degrad.) = 60% vs. 44% vs. 53%), whereas the heavy fraction was less degraded in comparison to the light fraction. It can be concluded, that the tree species-specific wood quality is a significant control of the impact on the degradation of hydrocarbons, and pine wood chips might be promising, possibly caused by their lower decomposability and lower substrate replacement than the other wood species.


Assuntos
Petróleo/metabolismo , Árvores/classificação , Madeira/química , Carbono/análise , Hidrocarbonetos/análise , Nitrogênio/análise , Picea/metabolismo , Pinus sylvestris/metabolismo , Solo/química , Enxofre/análise
4.
J Antimicrob Chemother ; 61(6): 1359-61, 2008 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-18343802

RESUMO

OBJECTIVES: Data are scarce on the long-term efficacy of lopinavir/ritonavir monotherapy for the maintenance of HIV suppression. Four years of results of patients randomized to monotherapy in the Only Kaletra (OK) pilot clinical trial are presented. PATIENTS AND METHODS: Twenty-one HIV-infected patients with suppressed HIV replication (<50 copies/mL) for at least 6 months and without previous failure while receiving a protease inhibitor-based regimen started lopinavir/ritonavir monotherapy. Follow-up was performed within the OK pilot clinical trial during the first 2 years and according to routine clinical practice during the 3rd and 4th years. RESULTS: Fourteen patients (67%) remain on monotherapy and with RNA <50 copies/mL (intention-to-treat analysis, with missing patients scored as failures). Five patients (24%) had virological rebound and all of them were successfully re-suppressed by adding two nucleosides. No major protease inhibitor mutations were found. CONCLUSIONS: Our data support the long-term efficacy and safety of lopinavir/ritonavir monotherapy for the maintenance of HIV suppression, a finding that must be confirmed in larger studies.


Assuntos
Infecções por HIV/tratamento farmacológico , Infecções por HIV/virologia , Inibidores da Protease de HIV/uso terapêutico , Pirimidinonas/uso terapêutico , Ritonavir/uso terapêutico , Adulto , Farmacorresistência Viral/genética , Feminino , HIV/genética , HIV/isolamento & purificação , Humanos , Estudos Longitudinais , Lopinavir , Masculino , Mutação , RNA Viral/sangue , Resultado do Tratamento , Carga Viral
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA